Homepage / Investment / Cramer reveals the biggest winners and losers from the JP Morgan Healthcare Conference
Amazon says this Prime Day was its biggest shopping event ever Kudlow says President Trump is 'so dissatisfied' with China trade talks that he is keeping the pressure on As stocks regain their footing, an ominous warning looms Goldman Sachs downgrades Clorox to sell, says valuation is 'unsustainably high' How Satya Nadella has spurred a tripling of Microsoft's stock price in just over four years Kudlow says economic growth could top 4% for 'a quarter or two,' more tax cuts could be coming The one chart that explains Netflix’s stunning comeback US housing starts plunge 12% in June to a nine-month low Aerospace titans Boeing and Airbus top $110 billion in orders at Farnborough Target uses Prime Day to its advantage, logging its 'biggest online shopping day' so far this year Billionaire Marc Lasry sees bitcoin reaching up to $40,000 as it becomes more mainstream and easier to trade These are the 10 US airports where you're most likely to be hacked Amazon shares slightly higher as investors await Prime Day results Wreck of Russian warship found, believed to hold gold worth $130 billion A bullish ‘phenomenon’ in bond market is weeks away from fading, top credit strategist says Stocks making the biggest moves premarket: MS, GOOGL, TXN, UAL, NFLX & more Twitter shares up 50% since late April means most upside priced in, analyst says in downgrade EU fines Google $5 billion over Android antitrust abuse Mortgage applications fall 2.5% as buyers struggle to find affordable homes America may not have the tools to counter the next financial crisis, warn Bernanke, Geithner and Paulson Investors are getting spooked as the risk of a no-deal Brexit rises EU expected to fine Google $5 billion over Android antitrust abuse Ex-FBI chief James Comey urges Americans to vote for Democrats in midterm elections Elon Musk apologizes to British cave diver following baseless 'pedo guy' claim Disney, Comcast and Fox: All you need to know about one of the biggest media battles ever Xiaomi shares notch new high after Hong Kong, mainland China stock exchanges reach agreement The trade war is complicating China's efforts to fix its economy European markets set for a strong open amid earnings; Google in focus Hedge fund billionaire Einhorn places sixth in major poker tournament The biggest spender of political ads on Facebook? President Trump Asian stocks poised to gain after Fed's Powell gives upbeat comments; dollar firmer Stocks are setting up to break to new highs Not all FAANG stocks are created equal EU ruling may be too little, too late to stop Google's mobile dominance Cramer explains how Netflix's stock managed to taper its drop after disappointing on earnings Airbnb condemns New York City's 'bellhop politics,' threatens legal retaliation Amazon sellers say they were unfairly suspended right before Prime Day, and now have two bad choices Investor explains why 'duller' tech stocks can have better returns than 'high-flying' tech names Elon Musk is 'thin-skinned and short-tempered,' says tech VC Texas Instruments CEO Brian Crutcher resigns for violating code of conduct Google Cloud Platform fixes issues that took down Spotify, Snapchat and other popular sites Uber exec: We want to become the 'one stop' transportation app 'What a dumb hearing,' says Democrat as Congress grills tech companies on conservative bias Amazon shares rebound, report says Prime Day sales jumped 89 percent in first 12 hours of the event How to put your medical history on your iPhone in less than 5 minutes Investment chief: Watch these two big events in 2018 Even with Netflix slowing, the market rally is likely not over Cramer: Netflix subscriber weakness debunks the 'sky's the limit' theory on the stock Netflix is looking at watch time as a new area of growth, but the competition is stiff Why Nobel laureate Richard Thaler follows Warren Buffett's advice to avoid bitcoin Rolls-Royce is developing tiny 'cockroach' robots to crawl in and fix airplane engines After Netflix plunge, Wall Street analysts forecast just tame returns ahead for the once high-flying FANG group Roku shares rise after analyst raises streaming video company's price target due to customer growth China is investing 9 times more into Europe than into North America, report reveals Amazon says US Prime Day sales 'so far bigger than ever' as glitch is resolved Netflix is on pace for its worst day in two years US lumber producers see huge opportunity, rush to expand San Francisco to consider tax on companies to help homeless Homebuilder sentiment, still high, stalls as tariffs, labor and land drive up costs Powell backs more rate hikes as economy growing 'considerably stronger' Netflix history is filled with big stock declines – like today – followed by bigger rebounds Intel shares get downgraded by Evercore ISI due to rising competition from Nvidia, AMD Petco aims to reinvent the pet store with something you can't buy online Genetic testing is coming of age, but for consumers it's buyer beware Tech 'FAANG' was the most-crowded trade in the world heading into the Netflix implosion, survey shows Netflix weak subscriber growth may indicate a 'maturity wall' that could whack the stock even more: Analyst This chart may be predicting the bull market's demise Wall Street says Netflix's stock plunge is a ‘compelling’ buying opportunity because the streaming giant ‘never misses twice’ Tesla sinks after Musk tweets, again Boeing announces new division devoted to flying taxis Stocks making the biggest move premarket: NFLX, UNH, GS, AMZN, WMT & more Deutsche Bank downgrades Netflix, but says big subscriber miss is not 'thesis changing' IBM is experimenting with a cryptocurrency that’s pegged to the US dollar North Korea and Zimbabwe: A friendship explained Virgin Galactic spinoff Orbit to launch rockets from the UK with space deal Artificial intelligence will create more jobs than it destroys? That’s what PwC says ‘Treasonous’ Trump and ‘Putin’s poodle:' Scathing headlines follow the Trump-Putin summit China’s fintech companies offer ‘enormous’ opportunity, investment manager says Trump's performance at summit with Putin was 'unprecedented,' experts say Walmart and Microsoft link up on cloud technology as they both battle Amazon European stocks seen mixed amid earnings; Fed’s Powell to address Congress How I knew I should quit my day job and run my start-up full-time: Viral website founder China's stocks have been trounced, but the trade war may ultimately be good news for those shares Billionaire tech investor Peter Thiel bets on crypto start-up Block.one Asian shares subdued open after mixed close on Wall Street; energy stocks under pressure Amazon cloud hits snags after Amazon Prime Day downtime Netflix isn't doomed by one quarter unless people start questioning the long-term investor thesis Tech stocks set to sink on Tuesday after rough evening for ‘FANG’ Netflix plummets after missing big on subscriber growth This wristband lets humans control machines with their minds The U.S. has a rocky history convincing Russia to extradite computer criminals Amazon suffers glitches at the start of Prime Day Jeff Bezos is now the richest man in modern history 'The United States has been foolish': Read Trump and Putin's full exchange Goldman Sachs recommends these 5 highly profitable companies — including Nvidia — to combat rising inflation Goldman Sachs releases 'tactical' stock picks for this earnings season Three red flags for Netflix ahead of its earnings report The bond market may be raising recession fears, but don't expect one anytime soon Cramer: Banks are 'making fortunes' but are still as hated as they were during the financial crisis Putin told Trump at summit: Russia never meddled in US election

Investment

Cramer reveals the biggest winners and losers from the JP Morgan Healthcare Conference

Of all the major conferences that kicked off 2018 — from the ICR confab to the tech-laden CES — the J.P. Morgan Healthcare Conference was the most important for CNBC’s Jim Cramer.

“This meeting tends to make major waves in the health care stocks,” the “Mad Money” host said. “The problem is the announcements from these pharma and biotech companies often read like they’re written in hieroglyphics. It can be very difficult to understand this stuff without a medical degree or a PhD in chemistry.”

So, to help investors make sense of what often proves to be a groundbreaking event, Cramer went through the biggest winners and losers from J.P. Morgan’s San Francisco, California-based health care convention.

Coming in first in terms of stock performance was Atara Biotherapeutics, up 52 percent since the start of 2018. Most of its move came after the J.P. Morgan conference.

The cause? Atara, a small company that develops immunotherapy treatments for cancer and multiple sclerosis, announced that the FDA approved one of its multiple sclerosis drugs for a Phase 1 study.

Better yet, Atara has a treatment for the Epstein-Barr virus (which causes mononucleosis, or mono) in Phase 3 trials — one step away from an FDA review.

“Put it all together, though, and it feels like the investors are warming to speculative biotechs again, even with the tape showing signs of raggedness today,” Cramer said on Tuesday.

Up 47 percent for the year, Alder Biopharmaceuticals was the conference’s second-biggest winner. Another small, development-stage biotechnology player, Alder announced strong clinical trial outcomes for its top medication, a migraine prevention drug.

“I like the story that CEO Randall Schatzman told us last week,” Cramer said. “But remember, Alder’s still a very early-stage company and there are plenty of pitfalls remaining before FDA approval, including, by the way, the fact that some competitors are ahead of them in the process.”

Other notable winners include Coherus Biosciences, a generic drugmaker with a 43 percent gain, and Illumina, a DNA-sequencing play up over 10 percent after the company introduced a new, low-cost sequencing machine.

(Cramer did caution investors about Coherus, which he saw as a commodity business with no patent protection.)

The J.P. Morgan Healthcare Conference’s biggest loser by far was Axovant Sciences, a company working on treatments for Alzheimer’s disease and dementia.

Cramer has watched Axovant’s stock get totally decimated in recent months, the first wave of losses coming after the Phase 3 clinical trial for its lead drug missed the mark.

The second negative wave came after the same drug failed to reach its primary endpoint in studies for treating dementia; the third came after Axovant announced that it had wrongly released positive data about a separate treatment for hallucinations.

“That’s how a stock goes from $5 to $2,” Cramer said. “I think this is a powerful reminder of what happens when you buy a stock without doing the homework, especially when you’re dealing with a overly promotional management team.”

Tesaro, which makes cancer-related drugs, came in second among the losers, with a stock down more than 20 percent since the beginning of 2018.

Cramer attributed the decline to the fact that Tesaro recently had to change the label on one of its treatments for chemotherapy-induced nausea to include that one of its side effects was anaphylactic shock — a life-threatening allergic reaction.

Next up for the biggest losers was Clovis Oncology, another cancer treatment maker with a stock down big for no real reason, the “Mad Money” host said.

“There wasn’t really anything particularly bad about the presentation,” Cramer said. “In fact, Clovis had a lot of good things going on for it, especially when it comes to treating ovarian cancer and solid tumors, yet it can’t seem to get any credit from Wall Street. That’s intriguing.”

Shares of Incyte got hit hard after the conference, but the company didn’t report any bad news. Cramer said the real problem was that health care giant Celgene is buying Incyte’s competitor, Impact Biomedicines, and the budding rivalry pushed investors out of Incyte’s stock.

Cramer was also keeping a hawk’s eye on Allergan after a tough 2017 for the Botox maker. But even after the company gave Wall Street weaker-than-expected guidance, the stock still managed to rally.

“CEO Brent Saunders painted a very compelling longer-term vision of the company’s future in his presentation. Suddenly, Allergan seems to be getting traction again,” Cramer said. “We just need to hear something that gives investors a reason to buy the stock beyond the fact that it’s cheap.”

The stock of Intuitive Surgical, the biotech behind the innovative da Vinci surgical robot, is also surging after a positive earnings pre-announcement. Cramer said he would stick with that name.

“Here’s the bottom line: we got a lot of good news from the J.P. Morgan Healthcare Conference last week, but if this confab showed us one thing, it’s that you need to be very careful when you speculate in small-cap biotech stocks, because the difference between the biggest winners and the biggest losers is enormous,” the “Mad Money” host concluded.

Disclosure: Cramer’s charitable trust owns shares of Allergan.

Questions for Cramer?
Call Cramer: 1-800-743-CNBC

Want to take a deep dive into Cramer’s world? Hit him up!
Mad Money TwitterJim Cramer TwitterFacebookInstagramVine

Questions, comments, suggestions for the “Mad Money” website? madcap@cnbc.com

Source: Investment Cnbc
Cramer reveals the biggest winners and losers from the JP Morgan Healthcare Conference

Comments are closed.